SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 226 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $737,057 | -19.5% | 26,734 | -12.2% | 0.00% | -25.0% |
| Q2 2023 | $915,297 | -20.2% | 30,449 | -3.9% | 0.00% | -20.0% |
| Q1 2023 | $1,147,585 | +102271.5% | 31,675 | +0.8% | 0.01% | 0.0% |
| Q4 2022 | $1,121 | +5.4% | 31,435 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $1,064 | -99.9% | 31,435 | +12.0% | 0.01% | +25.0% |
| Q2 2022 | $812,000 | -19.4% | 28,064 | -10.0% | 0.00% | 0.0% |
| Q1 2022 | $1,007,000 | +22.8% | 31,174 | +10.8% | 0.00% | +33.3% |
| Q4 2021 | $820,000 | +9.2% | 28,129 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $751,000 | -18.5% | 28,129 | -6.1% | 0.00% | -25.0% |
| Q2 2021 | $922,000 | +1.4% | 29,945 | -13.7% | 0.00% | 0.0% |
| Q1 2021 | $909,000 | -14.7% | 34,712 | -18.1% | 0.00% | -20.0% |
| Q4 2020 | $1,066,000 | +25.7% | 42,387 | +4.1% | 0.01% | +25.0% |
| Q3 2020 | $848,000 | -9.1% | 40,704 | +3.7% | 0.00% | -20.0% |
| Q2 2020 | $933,000 | +47.4% | 39,269 | +11.5% | 0.01% | +25.0% |
| Q1 2020 | $633,000 | -32.7% | 35,216 | -11.3% | 0.00% | 0.0% |
| Q4 2019 | $941,000 | -18.6% | 39,685 | -5.6% | 0.00% | -20.0% |
| Q3 2019 | $1,156,000 | -7.7% | 42,060 | +11.2% | 0.01% | -16.7% |
| Q2 2019 | $1,252,000 | -10.3% | 37,825 | -5.0% | 0.01% | -14.3% |
| Q1 2019 | $1,395,000 | +9.4% | 39,823 | +3.8% | 0.01% | 0.0% |
| Q4 2018 | $1,275,000 | -29.9% | 38,370 | +6.2% | 0.01% | -22.2% |
| Q3 2018 | $1,819,000 | -13.2% | 36,132 | +3.2% | 0.01% | -18.2% |
| Q2 2018 | $2,096,000 | +26.3% | 35,021 | -3.4% | 0.01% | +37.5% |
| Q1 2018 | $1,660,000 | +4.0% | 36,245 | -9.5% | 0.01% | +14.3% |
| Q4 2017 | $1,596,000 | -10.1% | 40,051 | -9.8% | 0.01% | -22.2% |
| Q3 2017 | $1,776,000 | -11.2% | 44,412 | -4.2% | 0.01% | -10.0% |
| Q2 2017 | $1,999,000 | +37.7% | 46,379 | 0.0% | 0.01% | +42.9% |
| Q1 2017 | $1,452,000 | +46.1% | 46,379 | +17.8% | 0.01% | +40.0% |
| Q4 2016 | $994,000 | +2.1% | 39,380 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $974,000 | +79.0% | 39,380 | +47.3% | 0.01% | +66.7% |
| Q2 2016 | $544,000 | +33.3% | 26,730 | 0.0% | 0.00% | +50.0% |
| Q1 2016 | $408,000 | +16.2% | 26,730 | +2.4% | 0.00% | 0.0% |
| Q4 2015 | $351,000 | -10.2% | 26,100 | +13.5% | 0.00% | 0.0% |
| Q2 2015 | $391,000 | – | 23,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |